Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
← catalyst calendarSponsored by Veradermics, Inc. (industry) · MANE — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
153actual
Sites
16
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-28 | actual | When the study began enrolling |
| Primary completion | 2025-02-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-02-25 | actual | The whole study's end, after follow-up |
| First posted | 2023-04-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Verruca Vulgaris
- Warts
- Common Wart
Interventions
- Drug: VDMN-21 Patch Low Dose
- Drug: VDMN-21 Patch High Dose
- Drug: Vehicle Patch
Primary outcome
what the primary-completion date above is the date OFProportion of subjects with complete clinical resolution of the Target Lesion at end of treatment period
measured Baseline up to Day 134
Permalink · MANE's whole pipeline · Catalyst calendar · Every registered study · What changed